FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data
source: shutterstock.com

FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data

Clinical-stage biotechnology company Abeona Therapeutics ("Abeona") is working to develop a novel cell therapy for people living with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder characterized by…

Continue Reading FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data
ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada
Source: www.pixabay.com

ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada

On December 13, 1996, Health Canada issued a policy statement called Priority Review of Drug Submissions which: provided for the "fast-tracking" of eligible New Drug Submissions (NDS) and Supplemental New…

Continue Reading ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada
Rare Community Profiles: How Two Parents Are Working to Change the Narrative Around CASK Gene Disorder
Fotocitizen / Pixabay

Rare Community Profiles: How Two Parents Are Working to Change the Narrative Around CASK Gene Disorder

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: How Two Parents Are Working to Change the Narrative Around CASK Gene Disorder
Zeposia Trial for Crohn’s Disease Falls Short
source: pixabay.com

Zeposia Trial for Crohn’s Disease Falls Short

Zeposia (ozanimod), developed by Bristol Myers Squibb, is an orally administered sphingosine 1-phosphate (S1P) receptor that is currently approved for two separate indications: relapsing multiple sclerosis and ulcerative colitis. According…

Continue Reading Zeposia Trial for Crohn’s Disease Falls Short
May is Lupus Awareness Month!
https://pixabay.com/en/flower-rain-macro-detail-purple-641401/

May is Lupus Awareness Month!

Also known as systemic lupus erythematosus (SLE), lupus is a chronic autoimmune disorder in which the immune system mistakenly attacks different parts of the body such as the joints, kidneys,…

Continue Reading May is Lupus Awareness Month!
Rare Community Profiles: When Sierra’s Son Was Diagnosed with Warsaw-Breakage Syndrome (WABS), She Knew She Needed to Make a Difference
source: pixabay.com

Rare Community Profiles: When Sierra’s Son Was Diagnosed with Warsaw-Breakage Syndrome (WABS), She Knew She Needed to Make a Difference

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: When Sierra’s Son Was Diagnosed with Warsaw-Breakage Syndrome (WABS), She Knew She Needed to Make a Difference
Transcranial Direct Current Stimulation Appears Effective in Parkinson’s-Related Pain
source: shutterstock.com

Transcranial Direct Current Stimulation Appears Effective in Parkinson’s-Related Pain

According to a story from psypost.org, a treatment approach called transcranial direct current stimulation can help alleviate certain aspects of pain associated with Parkinson's disease. Transcranial direct current stimulation (tDCS)…

Continue Reading Transcranial Direct Current Stimulation Appears Effective in Parkinson’s-Related Pain

RECAP: My Time at the PBCers 2024 Patient Education Conference: “Empowering Connections in PBC”

What’s better than being in warm and sunny Arizona? Getting to learn alongside the amazing primary biliary cholangitis (PBC) community while there! The PBCers organization held its 2024 Patient Education…

Continue Reading RECAP: My Time at the PBCers 2024 Patient Education Conference: “Empowering Connections in PBC”
Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia
source: shutterstock.com

Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia

Exa-cel Gene-Edited Therapy Vertex Pharmaceutical recently announced that Health Canada has accepted its New Drug Submission and granted Priority Review for Exa-cel, a gene-edited cell therapy, for the treatment of…

Continue Reading Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia

TMDU Researchers Develop Mouse Model for Anti-MDA5 Antibody-Positive Dermatomyositis

Developing an animal model of a disease can play an important role in both helping researchers to better understand that disease, as well as identifying and testing potential therapeutics. Animal…

Continue Reading TMDU Researchers Develop Mouse Model for Anti-MDA5 Antibody-Positive Dermatomyositis
April 30th is the First-Ever AMKD Awareness Day. Here’s What You Need to Know
source: shutterstock.com

April 30th is the First-Ever AMKD Awareness Day. Here’s What You Need to Know

  On April 30, 2024, the American Kidney Fund (AKF) will be organizing the first annual APOL1-mediated kidney disease (AMKD) Awareness Day. This awareness day will be a time to…

Continue Reading April 30th is the First-Ever AMKD Awareness Day. Here’s What You Need to Know